Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > International Molecular Screening Program for… >
International Molecular Screening Program for Metastatic Breast Cancer AURORA at IMPAKT

Published: May 7, 2014.
By Breast International Group (BIG)-aisbl
http://www.bigagainstbreastcancer.org

While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. Moreover, despite the fact that the overall breast cancer death rate has dropped steadily over the last decade and significant improvements in survival have been made, metastatic breast cancer represents the leading cause of death among patients with the disease.

In this context the Breast International Group (BIG) recently launched AURORA, which will use molecular screening to improve our understanding of metastatic breast cancer and its response or lack of response to available drug therapies. In total 1300 women and men from about 60 hospitals in 15 European countries are expected to take part in the programme. Over time, BIG hopes to expand the programme well beyond Europe to involve several 1000 more patients.

Dr Martine Piccart-Gebhart, Chair of BIG and Director of the Medicine Department of the Institut Jules Bordet, strongly believes in this research programme and says: "It is almost unethical that we continue to treat women with metastatic breast cancer when we have so little knowledge of their disease. We now have powerful technologies for investigating the molecular landscape of tumours, and we have an obligation to women to establish AURORA as a large translational research effort that can hopefully lead to more effective treatments in the future".

Within AURORA, metastatic and primary breast cancer tissue specimens will be collected and screened with a panel of more than 400 cancer-related genes for the first time on a large scale. Plasma and blood samples will also be collected, and any samples not analysed immediately will be stored in an independent bio-repository to enable future research. An innovative bioinformatics platform has been developed to support the collection of AURORA data. These data are being collected in a way that will allow sharing and collaborating in the context of other initiatives started by researchers in North America.

AURORA will enable scientists to understand both why breast cancer metastasises and why some patients respond poorly to standard treatment, while others respond very well. Whenever possible, patients participating in AURORA will be offered to participate in a clinical trial testing new and promising drugs that target the specific genetic characteristics of their tumours. The ultimate hope is that AURORA will benefit patients by leading us to both better treatments and to finding cures for the women and men affected by this disease.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Disease 
12/23/11 
UK Researchers Present Findings from Kentucky Breast Cancer Patients with Disease Relapse
By University of Kentucky
The University of Kentucky Markey Cancer Center breast oncologist Dr. Suleiman Massarweh and his research team presented findings from their studies on relapse of breast cancer at the San …
Cancer 
1/27/14 
Drug to Reverse Breast Cancer Spread in Development
By Cardiff University
Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells. The vast majority of deaths from cancer result from …
Dock1 
4/15/13 
An Important Discovery in Breast Cancer by IRCM Researchers
By Institut de recherches cliniques de Montreal
Montréal, April 15, 2013 – A team of researchers at the IRCM, led by Dr. Jean-François Côté, made an important discovery in breast cancer, which will published online this …
Treatment 
3/24/10 
What Should Be the Goal of Treatment in Metastatic Breast Cancer?
By ECCO-the European CanCer Organisation
Barcelona, Spain: Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over …
Breast 
8/3/11 
Research Explores How Breast Cancer Spreads And New Ways to Treat It
By US Department of Defense Congressionally Directed Medical Research Programs
ORLANDO, Fla. — August 3, 2011 — Research into new methods to prevent and slow metastatic breast cancer will be presented this week at the Era of Hope conference, …
Patients 
12/13/13 
New Combination Therapy Fails to Delay Progression of Advanced Breast Cancer
By American Association for Cancer Research
SAN ANTONIO — Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of …
Treatment 
3/26/10 
Beta-blockers Help Reduce Metastasis And Improve Survival in Breast Cancer Patients
By ECCO-the European CanCer Organisation
Barcelona, Spain: Treatment with beta-blockers can help reduce the spread of cancer in patients with breast tumours, a researcher will tell the seventh European Breast Cancer Conference (EBCC7) in …
Cancer 
9/10/14 
CNIO Successfully Completes Its Fisrt Clinical Trial on HER-2-negative Breast Cancer with Nintedanib
By Centro Nacional de Investigaciones Oncologicas (CNIO)
The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumours in 50% of patients suffering from early HER-2- negative breast cancer, the most …
Risk 
5/2/13 
Gene Expression Test Distinguishes Between Breast Cancer Patients at High And Low Risk of Late Recurrence
By European Society for Medical Oncology
Lugano-CH, Brussels-BE, 2 May 2013 -- A test that measures the expression levels of 58 genes in oestrogen receptor-positive breast cancers can effectively differentiate between patients who are at …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition